Stereotaxis (STXS) Net Income towards Common Stockholders (2010 - 2026)
Stereotaxis (STXS) posted quarterly Net Income towards Common Stockholders of -$6.2 million for Q1 2026, down 0.57% year-over-year from -$6.2 million in Q1 2025, and down 5.52% quarter-over-quarter from -$5.8 million in Q4 2025.
Stereotaxis (STXS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Stereotaxis (STXS) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$6.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 0.57% year-over-year to -$6.2 million; the TTM figure through Mar 2026 stood at -$23.0 million (up 13.89% YoY), while the FY2025 annual figure was -$22.9 million, up 9.62% from the prior year.
- Net Income towards Common Stockholders slipped to -$6.2 million in Q1 2026 per STXS's latest filing, from -$5.8 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$4.1 million in Q2 2025 and bottomed at -$7.8 million in Q4 2024.
- Historically, Net Income towards Common Stockholders has averaged -$5.7 million across 5 years, with a median of -$5.7 million in 2023.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 253.75% — and 2025, when it surged 32.71%.
- Stereotaxis' Net Income towards Common Stockholders stood at -$4.5 million in 2022, then decreased by 19.75% to -$5.4 million in 2023, then slumped by 45.73% to -$7.8 million in 2024, then increased by 25.39% to -$5.8 million in 2025, then declined by 5.52% to -$6.2 million in 2026.
- Business Quant data shows STXS's Net Income towards Common Stockholders at -$6.2 million in Q1 2026, -$5.8 million in Q4 2025, and -$6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 823.20 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 378.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 383.43 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 139.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 93.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -77.90 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 126.00 Mn |
| 10 | Stereotaxis | 141.91 Mn | 127.29 Mn | 3.79 Mn | -6.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.17 Mn |
| Dec 31, 2025 | -5.85 Mn |
| Sep 30, 2025 | -6.79 Mn |
| Jun 30, 2025 | -4.14 Mn |
| Mar 31, 2025 | -6.14 Mn |
| Dec 31, 2024 | -7.84 Mn |
| Sep 30, 2024 | -6.52 Mn |
| Jun 30, 2024 | -6.16 Mn |
| Mar 31, 2024 | -4.84 Mn |
| Dec 31, 2023 | -5.38 Mn |
| Sep 30, 2023 | -5.71 Mn |
| Jun 30, 2023 | -5.29 Mn |
| Mar 31, 2023 | -5.68 Mn |
| Dec 31, 2022 | -4.49 Mn |
| Sep 30, 2022 | -5.26 Mn |
| Jun 30, 2022 | -5.47 Mn |
| Mar 31, 2022 | -4.42 Mn |
| Dec 31, 2021 | -3.69 Mn |
| Sep 30, 2021 | -4.96 Mn |
| Jun 30, 2021 | -1.55 Mn |